ERRFY News and Press, Eurofins Scientific S.E. ADR

2023-08-05 10:40:00 ET Summary Eurofins is dealing with a revenue decrease due to the lack of COVID testing and the sale of reagents. Excluding the COVID-related revenue, the H1 2023 revenue would have increased by a high single digit percentage. The company slightly reduced i...

Summary Eurofins is a large life sciences company, but its COVID tailwinds are coming to an end. Apparently the market is surprised by this. I am not. The current share price weakness offers an excellent opportunity for investors with a 5-year investment horizon. Eurofins' 2027 ...

Summary Eurofins Scientific printed cash during the COVID pandemic as its testing capacity was running at full utilization. There shouldn't be any massive post-COVID blues as growth in other domains should offset the decreasing COVID-related revenue. The company is now trading at ab...

Summary Eurofins’ latest buyback announcement comes on the heels of its first major divestment in years. Backed by a strong balance sheet, the company looks geared for more growth ahead. While the stock has suffered YTD, Eurofins’ underlying fundamentals remain a...

The fund's investment objective is long-term growth of capital. In pursuing this objective, it focuses on investing in equity securities that the advisor believes are undervalued at the time of purchase and have the potential for growth. For Q2 2021, Sequoia Fund generated a total ret...

Eurofins Scientific (ERRFY): FY Non-GAAP EPS of €3.63; GAAP EPS of €2.71.Revenue of €5.44B (+19.3% Y/Y)Press Release For further details see: Eurofins Scientific reports FY results

Eurofins Viracor Diagnostics Launches Combined Test For COVID-19, Influenza, And RSV As The Flu Season Approaches The combined test offers an efficient and highly sensitive method to detect multiple respiratory pathogens including COVID-19 and Flu to inform treatment decisions ...

Eurofins Transplant Diagnostics Introduces TruGraf Liver At AASLD - The Liver Meeting Novel Biomarker-Based Assay Confirms Immune Quiescence in Liver Transplant Patients PR Newswire MANSFIELD, Mass., Nov. 13, 2020 MANSFIELD, Mass. , Nov. 13, 2020 /PRNewsw...

Cooper Investors Pty Limited ("CI") is a specialist equities fund manager with funds under management of approximately A$13 billion. The portfolio returned 9.18% for the quarter versus 6.94% for the benchmark. Over a rolling 12 months the portfolio has returned 8.74% while the benchma...

The fund's investment objective is long-term growth of capital. In pursuing this objective, it focuses on investing in equity securities that the advisor believes are undervalued at the time of purchase and have the potential for growth. For Q3 2020, Sequoia Fund generated a total ret...